A Randomized, Placebo-Controlled, Double-Blind Pilot Study of Pioglitazone Hydrochloride in Severe, Refractory Asthma

National Institutes of Health (NIH)

Status and phase: Completed; Phase 2

Conditions: Severe, Refractory Asthma; Airway Inflammation; Airflow Obstruction

Treatments: Drug: Placebo; Drug: Pioglitazone

Study type: Interventional

Funder types: NIH

Identifiers

NCT00994175

090244

09-H-0244 (Other Identifier)

Details and patient eligibility

About

Background:

• Individuals who have severe asthma that is not easily controlled by current treatments are in need of new treatments to prevent potentially life-threatening asthma attacks. Experiments in mice have found that a medication called pioglitazone hydrochloride (Actos ), which is used to treat patients with diabetes, may be effective for treating severe asthma. Researchers are interested in determining whether Actos is effective in improving the quality of life in subjects with severe asthma who continue to have symptoms despite maximum standard medical therapy.

Objectives:

• To assess the effectiveness of pioglitazone hydrochloride as a treatment for patients with severe asthma that is not controlled by standard treatments.

Eligibility:

• Individuals between 18 and 75 years of age who have been diagnosed with and treated for severe asthma for at least 1 year.

Design:

• Potential participants will have a screening visit to determine eligibility for the study. The visit will involve breathing tests, chest x rays, heart and lung monitoring, and blood tests.
• Eligible participants will have a full medical history and will answer a series of questionnaires about their quality of life with asthma.
• Phase 1: Patients will record lung function and asthma symptoms morning and evening for 4 weeks. At the end of this period, patients will be evaluated with breathing, allergy, and blood tests, as well as questionnaires. Patients will also provide a sputum sample.
• Phase 2: Patients will receive regular doses of either pioglitazone hydrochloride or a placebo for 16 weeks. Patients will return to the National Institutes of Health every 4 weeks for tests.
• Phase 3: Wash-out period without study drugs for 4 weeks, similar to Phase 1.
• Phase 4: Patients will receive regular doses of either pioglitazone hydrochloride or a placebo for 16 weeks. Patients who received placebo will be given the study drug, and vice versa. Patients will return to the National Institutes of Health every 4 weeks for tests.
• Phase 5: Medications will be stopped, and patients will return to the National Institutes of Health 4 weeks later for final tests.

Full description

New therapies are needed for patients with asthma who are sub-optimally controlled by standard measures. Pioglitazone hydrochloride (Actos ) is a highly selective and potent agonist for the peroxisome proliferator-activated receptor-Gamma (PPAR Gamma). Studies in murine models of allergic asthma have shown that PPAR Gamma agonists down-regulate allergen-mediated airway inflammation and airway hyperresponsiveness. This protocol is a randomized, placebo-controlled, doubleblind, crossover (phase II) pilot study of the efficacy of pioglitazone for the treatment of patients with severe, refractory asthma. The primary end-point for this study will be quality of life as determined by the Asthma Quality of Life Questionnaire (AQLQ) score. Secondary end-points will include indices of airway inflammation, airflow obstruction, airway hyperreactivity, and asthma symptoms.

Enrollment: 15 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

• INCLUSION CRITERIA:
• Subjects will be between 18 and 75 years of age, male or female, with a diagnosis of severe, refractory asthma, as defined by the American Thoracic Society, for at least one year.
• Subjects must have a history of reversible airflow obstruction as defined by a positive methacholine bronchoprovocation challenge or a positive response to inhaled bronchodilators at some point in the course of their disease or a greater than 20% variability in the Forced Expiratory Volume in 1 second (FEV1) or the peak expiratory flow (PEF) documented during serial measurements of lung function over time.
• Left ventricular ejection fraction greater than or equal to 50% by echocardiogram
• For women of childbearing potential, negative pregnancy test prior to study and willingness to adhere to reliable birth control methods during the study.
• Subjects must have the ability to provide informed consent

EXCLUSION CRITERIA:

• A known history of hypersensitivity to pioglitazone.

• Asthma exacerbation requiring treatment with additional oral corticosteroids in the previous 6 weeks, or a life-threatening asthma attack requiring cardiopulmonary support in the previous 6 months.

• Cigarette smoking within the previous 12 months or a prior history of > 20 cumulative pack-years.

• Investigational therapy for any indication within I month prior to the screening visit.

• History of lung disease other than asthma (ie., COPD, sarcoidosis).

• History of diabetes mellitus requiring treatment with any medication, insulin secreting tumor, or symptomatic hypoglycemia.

• HIV/AIDS

• History of congestive heart failure with current symptoms consistent with NYHA classification II, Ill or IV.

• Preexisting edema (2+ or greater).

• Hemoglobin < 11 gm/dl for males and < 10 gm/dl for females.

• Active liver disease or abnormal liver function tests > 2 times upper limit of normal.

• History of bladder or colon cancer.

• History of other cancer not in remission.

• Active breast feeding.

• Use of the following medications, which can interact with pioglitazone:

  • Gemfibrizol (Lopid)
  • Atazanivir (Reyataz)
  • Ritonavir (Norvir)
  • Rifampin (Rifadpin)
  • Carbamzepine (Tegretol)
  • Phenobarbital (Luminal)
  • Phenytoin (Dilantin)
  • Rifapentine (Priftin)
  • Secobarbital (Seconal)
  • Amiodarone (Cordarone, Pacerone)
  • Palitaxel (Taxol)
  • Replaglinide (Prandine)
  • Ketoconazole (Nizoral)
  • Atorvastatin (Lipitor )
  • Fosphenytoin (Cerebyx)
  • Itraconazole (Sporanox)
  • Trimethoprim (in Bactrim)
  • Thioridazine

• Certain over-the-counter herbs and supplements. These will be reviewed by the investigators for possible interactions with the study medication A determination of whether the supplement is safe to use with pioglitazone will be made on a case-by-case basis.

• Any condition that, in the investigator s opinion, places the patient at undue risk for complications from pioglitazone therapy.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

15 participants in 2 patient groups

Pioglitazone, Then Placebo

Experimental group

Description:

Pioglitazone, 30 mg daily, was administered for the initial 2 weeks of the first treatment phase, followed by 45 mg daily for an additional 14 weeks. This was followed by a 4-week washout period. Subjects were assessed for clinical stability during a second 4-week run-in period prior to crossing over to the placebo phase for 16 weeks in the second treatment phase to receive the placebo.

Treatment:

Drug: Placebo

Drug: Pioglitazone

Placebo, Then Pioglitazone

Experimental group

Description:

Placebo was administered for 16 weeks. This was followed by a 4-week washout period. Subjects were assessed for clinical stability during a second 4-week run-in period prior to crossing over to the Pioglitazone treatment group. Pioglitazone, 30 mg daily, was administered for the initial 2 weeks of the treatment phase, followed by 45 mg daily for an additional 14 weeks.

Treatment:

Drug: Placebo

Drug: Pioglitazone